CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 12 enrolled
Drug / intervention
erlotinib +2 moredrug
Likely dose
erlotinib 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02556593
NCT02556593Phase 2Terminated
Terminated
CompareCT.gov

IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Sun Yat-sen University·interventional·Posted Sep 22, 2015·Updated Apr 12, 2019

In Brief

A Phase 2 clinical trial evaluating IMRT, WBRT, and 1 other intervention for Non-Small Cell Lung Carcinoma. Terminated early, enrolled 12 participants across 1 site.

Signals

Trial was terminated early

Detailed Summary

This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2TerminatedFinished
20162017201820192020202120222023202420252026
First PostedSep 22, 2015
Enrollment StartSep 1, 2015
Primary CompletionApr 1, 2019
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 10.8 years ago

Interventions

IMRTradiation

Daily IMRT at 45 Gy in 15 fractions to brain metastases

WBRTradiation

3DCRT at 30 Gy in 10 fractions to whole brain

erlotinibdrug

erlotinib 150mg daily